Literature DB >> 34633844

Population Genomics Reveals Distinct Temporal Association with the Emergence of ST1 Serotype V Group B Streptococcus and Macrolide Resistance in North America.

M Belén Cubria1, Luis Alberto Vega1, William C Shropshire2, Misu A Sanson1, Brittany J Shah1, Shrijana Regmi1, Marcia Rench3, Carol J Baker1, Anthony R Flores1,4.   

Abstract

Identified in the 1970s as the leading cause of invasive bacterial disease in neonates and young infants, group B Streptococcus (GBS) is now also recognized as a significant cause of morbidity and mortality among adults with underlying medical conditions and the elderly. Concomitant with the increasing incidence of GBS invasive disease in adults is the rise of resistance among GBS isolates to second line antibiotics. Previous research shows that among serotype V GBS, one of the most common capsular types causing adult invasive disease, sequence type 1 (ST1), accounts for an overwhelming majority of adult invasive disease isolates and frequently harbors macrolide resistance. In this study, using whole-genome sequencing data from strains isolated in the United States and Canada over a 45-year period, we examined the association of antimicrobial resistance with the emergence of invasive serotype V ST1 GBS. Our findings show a strong temporal association between increased macrolide resistance and the emergence of serotype V ST1 GBS subpopulations that currently co-circulate to cause invasive disease in adults and young infants. ST1 GBS subpopulations are defined, in part, by the presence of macrolide resistance genes in mobile genetic elements. Increased frequency of macrolide resistance-encoding mobile genetic elements among invasive GBS ST1 strains suggests the presence of such elements contributes to GBS virulence. Our work provides a foundation for the investigation of genetic features contributing to the increasing prevalence and pathogenesis of serotype V GBS in adult invasive disease.

Entities:  

Keywords:  genomics; group B streptococcus; macrolide resistance; serotype V

Mesh:

Substances:

Year:  2021        PMID: 34633844      PMCID: PMC8765267          DOI: 10.1128/AAC.00714-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  62 in total

Review 1.  History of macrolide use in pediatrics.

Authors:  J O Klein
Journal:  Pediatr Infect Dis J       Date:  1997-04       Impact factor: 2.129

2.  Structural and genetic diversity of group B streptococcus capsular polysaccharides.

Authors:  Michael J Cieslewicz; Donald Chaffin; Gustavo Glusman; Dennis Kasper; Anup Madan; Stephani Rodrigues; Jessica Fahey; Michael R Wessels; Craig E Rubens
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

3.  Group B streptococcus bacteremia in nonpregnant adults.

Authors:  P Muñoz; A Llancaqueo; M Rodríguez-Créixems; T Peláez; L Martin; E Bouza
Journal:  Arch Intern Med       Date:  1997-01-27

4.  Characterization of invasive group B streptococcus strains from the greater Toronto area, Canada.

Authors:  Sarah Teatero; Allison McGeer; Donald E Low; Aimin Li; Walter Demczuk; Irene Martin; Nahuel Fittipaldi
Journal:  J Clin Microbiol       Date:  2014-02-19       Impact factor: 5.948

5.  Molecular epidemiology of group B streptococci in Ireland reveals a diverse population with evidence of capsular switching.

Authors:  Mary Meehan; Robert Cunney; Mary Cafferkey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-28       Impact factor: 3.267

Review 6.  Azithromycin: the first azalide antibiotic.

Authors:  C H Ballow; G W Amsden
Journal:  Ann Pharmacother       Date:  1992-10       Impact factor: 3.154

7.  Epidemiology of Invasive Group B Streptococcal Disease in Alberta, Canada, from 2003 to 2013.

Authors:  Areej Alhhazmi; Donna Hurteau; Gregory J Tyrrell
Journal:  J Clin Microbiol       Date:  2016-04-20       Impact factor: 5.948

8.  Population structure and antimicrobial resistance of invasive serotype IV group B Streptococcus, Toronto, Ontario, Canada.

Authors:  Sarah Teatero; Allison McGeer; Aimin Li; Janice Gomes; Christine Seah; Walter Demczuk; Irene Martin; Jessica Wasserscheid; Ken Dewar; Roberto G Melano; Nahuel Fittipaldi
Journal:  Emerg Infect Dis       Date:  2015-04       Impact factor: 6.883

9.  Molecular Characteristics and Antimicrobial Resistance of Group B Streptococcus Strains Causing Invasive Disease in Neonates and Adults.

Authors:  Ming-Horng Tsai; Jen-Fu Hsu; Mei-Yin Lai; Lee-Chung Lin; Shih-Ming Chu; Hsuan-Rong Huang; Ming-Chou Chiang; Ren-Huei Fu; Jang-Jih Lu
Journal:  Front Microbiol       Date:  2019-02-18       Impact factor: 5.640

Review 10.  A Vaccine Against Group B Streptococcus: Recent Advances.

Authors:  Clara Carreras-Abad; Laxmee Ramkhelawon; Paul T Heath; Kirsty Le Doare
Journal:  Infect Drug Resist       Date:  2020-04-29       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.